CO2022014882A2 - Inhibidor de ret cristalino - Google Patents

Inhibidor de ret cristalino

Info

Publication number
CO2022014882A2
CO2022014882A2 CONC2022/0014882A CO2022014882A CO2022014882A2 CO 2022014882 A2 CO2022014882 A2 CO 2022014882A2 CO 2022014882 A CO2022014882 A CO 2022014882A CO 2022014882 A2 CO2022014882 A2 CO 2022014882A2
Authority
CO
Colombia
Prior art keywords
crystalline
ret inhibitor
ret
crystalline form
diseases
Prior art date
Application number
CONC2022/0014882A
Other languages
English (en)
Inventor
Rajni Miglani Bhardwaj
Mark Steven Kerr
Douglas Patton Kjell
Jeremy Miles Merritt
Jon Gordon Selbo
Shekhar Krishna Viswanath
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of CO2022014882A2 publication Critical patent/CO2022014882A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Semiconductor Lasers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En el presente documento se proporciona una forma cristalina de selpercatinib útil en el tratamiento y prevención de enfermedades que pueden tratarse con un inhibidor de la quinasa RET, incluidos enfermedades y trastornos asociados con RET, y métodos para preparar esta forma cristalina.
CONC2022/0014882A 2020-04-17 2022-10-19 Inhibidor de ret cristalino CO2022014882A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063011701P 2020-04-17 2020-04-17
US202163151354P 2021-02-19 2021-02-19
PCT/US2021/026611 WO2021211380A1 (en) 2020-04-17 2021-04-09 Crystalline ret inhibitor

Publications (1)

Publication Number Publication Date
CO2022014882A2 true CO2022014882A2 (es) 2022-10-31

Family

ID=75747118

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0014882A CO2022014882A2 (es) 2020-04-17 2022-10-19 Inhibidor de ret cristalino

Country Status (17)

Country Link
EP (1) EP4136090A1 (es)
JP (1) JP2023522012A (es)
KR (1) KR20230002706A (es)
CN (1) CN115916791A (es)
AU (1) AU2021255488B2 (es)
BR (1) BR112022020446A2 (es)
CA (1) CA3174316A1 (es)
CL (1) CL2022002849A1 (es)
CO (1) CO2022014882A2 (es)
CR (1) CR20220520A (es)
DO (1) DOP2022000221A (es)
EC (1) ECSP22080982A (es)
IL (1) IL297212A (es)
MX (1) MX2022012952A (es)
PE (1) PE20230388A1 (es)
TW (1) TW202202501A (es)
WO (1) WO2021211380A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022069357A1 (en) * 2020-10-01 2022-04-07 Sandoz Ag Crystalline form of selpercatinib
AU2022416156A1 (en) 2021-12-13 2024-05-30 Loxo Oncology, Inc. Processes for the preparation of the crystalline form a of selpercatinib. a ret inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
TWI791053B (zh) * 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
TWI783057B (zh) * 2017-10-10 2022-11-11 美商絡速藥業公司 製備6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈的方法
TWI812649B (zh) * 2017-10-10 2023-08-21 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
US20210379056A1 (en) * 2018-09-30 2021-12-09 Applied Pharmaceutical Science, Inc. Substituted pyrazole fused ring derivative, preparation method therefor, and application thereof
CN111004257B (zh) * 2019-12-24 2021-06-29 武汉九州钰民医药科技有限公司 制备RET抑制剂Selpercatinib的方法

Also Published As

Publication number Publication date
KR20230002706A (ko) 2023-01-05
ECSP22080982A (es) 2023-01-31
CL2022002849A1 (es) 2023-06-16
AU2021255488A1 (en) 2022-11-10
IL297212A (en) 2022-12-01
JP2023522012A (ja) 2023-05-26
AU2021255488B2 (en) 2024-05-30
CA3174316A1 (en) 2021-10-21
CR20220520A (es) 2022-11-15
BR112022020446A2 (pt) 2022-11-29
DOP2022000221A (es) 2023-01-15
PE20230388A1 (es) 2023-03-06
MX2022012952A (es) 2023-01-11
TW202202501A (zh) 2022-01-16
EP4136090A1 (en) 2023-02-22
CN115916791A (zh) 2023-04-04
WO2021211380A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
CO2022014882A2 (es) Inhibidor de ret cristalino
DOP2019000163A (es) Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
CL2018000119A1 (es) Compuestos pirazolo[1,5-a]piridina sustituidos como inhibidores de quinasa de ret.
CL2018002708A1 (es) Métodos para la inhibición de la angiogénesis en un sujeto que lo necesita
ECSP18094983A (es) Derivados de pirazol como inhibidores de la calicreína plasmática
CR20190218A (es) Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
CR20150450A (es) Inhibidores quinazolínicos de formas mutadas activantes del receptor del factor de crecimiento epidérmico
CO2019001212A2 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos
CO2021006075A2 (es) Compuestos y composiciones para el tratamiento de afecciones asociadas con la actividad de nlrp
ECSP11010824A (es) Tratamiento para diabetes en pacientes inapropiados para terapia con metformina.
MX2022007221A (es) Compuestos y composiciones para el tratamiento o prevencion de trastornos patologicos asociados con exceso de deposicion de fibrina y/o formacion de trombos.
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
ZA202006072B (en) Ret inhibitor for use in treating cancer having a ret alteration
ECSP23057264A (es) Inhibidores de cdk2 y métodos de uso de los mismos
CO2021008535A2 (es) Compuestos de quinolina como inhibidores de quinasas tam y met
AR104755A1 (es) Método para el tratamiento de enfermedad neurológica
CO2019007879A2 (es) Formas cristalinas de tebipenem pivoxil, composiciones que incluyen a las mismas, métodos de fabricación, y métodos de utilización
CL2019000228A1 (es) Tratamiento conjunto contra tipos de cáncer hematológico.
BR112022001393A2 (pt) Forma cristalina do inibidor de atr e seu uso
DOP2018000197A (es) Compuestos de cinnolin-4-amina y su uso en el tratamiento del cáncer
CL2019002808A1 (es) Métodos para prevenir o tratar enfermedades oftálmicas.
AR095594A1 (es) Métodos para tratar infecciones en pacientes con sobrepeso y obesos usando antibióticos
CO2017005357A2 (es) Un proceso para la fabricación de idalopirdina
CO2023017186A2 (es) Formas cristalinas de trofinetida